[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342299-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342299-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","differential-effects-of-glp-1-receptor-agonists-on-cancer-risk-in-obesity-a-nationwide-analysis-of-11-million-patients","Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity - A Nationwide Analysis of 1.1 Million Patients","","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective for obesity and diabetes, yet their relationship to cancer risk remains uncertain. This nationwide cohort study evaluates GLP-1RA use and cancer incidence among adults with obesity across 5-year follow-up using the TriNetX US Collaborative Network (2013–2023). Propensity score matching (1:1) compares GLP-1RA-treated patients with matched controls and includes subgroup analyses by agent, sex, and BMI. Results show significant cancer-risk reductions overall, with semaglutide offering stronger protection, while liraglutide increases thyroid and respiratory cancer risk. Findings support potential dual benefits and personalized treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/differential-effects-of-glp-1-receptor-agonists-on-cancer-risk-in-obesity-a-nationwide-analysis-of-11-million-patients/342299/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/differential-effects-of-glp-1-receptor-agonists-on-cancer-risk-in-obesity-a-nationwide-analysis-of-11-million-patients/342299.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What data source and study design were used to evaluate cancer risk?","Question",{"text":63,"@type":64},"The study uses the TriNetX US Collaborative Network database (2013–2023) and follows adult patients with obesity for 5 years. Propensity score matching (1:1) pairs GLP-1RA-treated patients with matched controls using nearest-neighbor methods.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which GLP-1RA showed the strongest protective effects?",{"text":68,"@type":64},"Semaglutide demonstrated superior protective effects, particularly for gastrointestinal cancers (HR 0.45, 95% CI 0.37–0.53).",{"name":70,"@type":61,"acceptedAnswer":71},"Did all GLP-1RAs affect cancer risk in the same direction?",{"text":72,"@type":64},"No. The analysis found significant reductions across multiple cancer types overall, but liraglutide was associated with increased risks for thyroid cancer (HR 1.70) and respiratory cancers (HR 1.62).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342299,1790325339,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Article  \nDifferential Effects of GLP-1 Receptor Agonists on Cancer  \nRisk in Obesity: A Nationwide Analysis of 1.1 Million Patients  \nShauna Levy 1,*, Abdallah Attia 1, Rami M. Elshazli 1,2,3, Ahmed Abdelmaksoud 4, Danielle Tatum 1, Hani Aiash 5,† and Eman A. Toraih 1,6, *,†  \nAcademic Editor: Liliana Chemello  \nReceived: 15 November 2024  \nRevised: 13 December 2024  \nAccepted: 26 December 2024  \nPublished: 30 December 2024  \nCitation: Levy, S.; Attia, A.;  \nElshazli, R.M.; Abdelmaksoud, A.; Tatum, D.; Aiash, H.; Toraih, E.A. Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. Cancers 2025, 17, 78. [https://](https://)[ ](https://)[doi.org/10.3390/cancers17010078](doi.org/10.3390/cancers17010078)  \n[Copyright:](Copyright:) © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA; [aattia@tulane.edu](aattia@tulane.edu) (A.A.); [relshazli@tulane.edu](relshazli@tulane.edu) (R.M.E.); [dtatum@tulane.edu](dtatum@tulane.edu) (D.T.)  \n2 Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus University-Egypt, New Damietta 34517, Egypt  \n3 Department of Biological Sciences, Faculty of Science, New Mansoura University, New Mansoura City 35742, Egypt  \n4 Department of Internal Medicine, University of California, Riverside, CA 92521, USA; [ahmed.abdelmaksoud@medsch.ucr.edu](ahmed.abdelmaksoud@medsch.ucr.edu)  \n5 Department of cardiovascular perfusion, Upstate Medical University, Syracuse, NY 13210, USA; [aiashh@upstate.edu](aiashh@upstate.edu)  \n6 Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt  \n* Correspondence: [slevy10@tulane.edu](slevy10@tulane.edu) (S.L.); [etoraih@tulane.edu](etoraih@tulane.edu) (E.A.T.)† Contributed equally as senior authors to this manuscript.  \nSimple Summary: Glucagon-like peptide-1 receptor agonists are medications widely used for treating obesity and diabetes. While their metabolic benefits are well established, their potential impact on cancer risk remains unclear. This nationwide study of over 1.1 million patients examined how these medications affect cancer risk in people with obesity. Our research revealed that these drugs, particularly semaglutide, significantly reduced the risk of various cancers, though effects varied by specific medication type. These findings suggest that these medications may offer dual benefits in treating obesity while potentially reducing cancer risk, opening new possibilities for preventive medicine and personalized treatment approaches.  \nAbstract: Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management. This comprehensive study investigated the relationship between GLP-1RA use and cancer incidence in individuals with obesity across a 5-year follow-up period. Methods: We conducted a large-scale cohort study using the TriNetX US Collaborative Network database (2013–2023) examining adult patients with obesity. The study utilized propensity score matching to pair GLP-1RA-treated patients with controls (1:1) using the nearest neighbor method. Cancer incidence served as the primary outcome measure over the 5-year follow-up, with subgroup analyses considering individual GLP-1RA agents, patient sex, and BMI categories. Results: Analysis revealed significant cancer-risk reductions associated with GLP-1RA use across multiple cancer types compared to matched controls. Notable risk reductions were observed in gastrointestinal (HR ","cbCaipM1siDTuJQO","https://ap.wps.com/l/cbCaipM1siDTuJQO","pdf",1353471,17,"English","# Introduction\n# Materials and Methods\n## Study Design and Data Source\n## Propensity Score Matching\n## Outcomes and Subgroup Analyses\n# Results\n## Overall Cancer Incidence\n## Cancer-Specific Findings\n## Agent-Specific Effects\n# Discussion\n# Conclusions","[{\"question\":\"What data source and study design were used to evaluate cancer risk?\",\"answer\":\"The study uses the TriNetX US Collaborative Network database (2013–2023) and follows adult patients with obesity for 5 years. Propensity score matching (1:1) pairs GLP-1RA-treated patients with matched controls using nearest-neighbor methods.\"},{\"question\":\"Which GLP-1RA showed the strongest protective effects?\",\"answer\":\"Semaglutide demonstrated superior protective effects, particularly for gastrointestinal cancers (HR 0.45, 95% CI 0.37–0.53).\"},{\"question\":\"Did all GLP-1RAs affect cancer risk in the same direction?\",\"answer\":\"No. The analysis found significant reductions across multiple cancer types overall, but liraglutide was associated with increased risks for thyroid cancer (HR 1.70) and respiratory cancers (HR 1.62).\"}]","Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity - A Nationwide Analysis of 1.1 Million Patients | PDF",1790046050,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c549432074a32d2135fde9eb2787cae1.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ab7f57b0220c895548ab9241614de2a.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83edd47e6141acbf14d052a0accd32a8.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f868c305fb5f913c35d17575c8068bf.webp",980,1385]